Quantum Genesis AI Corp. has issued a statement regarding the Caveat Emptor designation placed on the company's securities by OTC Markets Group, Inc. on February 12, 2026. The technology company, which focuses on artificial intelligence, computational modeling, and scientific innovation, has made several attempts to communicate with OTC Markets since the designation was applied to better understand its basis and determine necessary steps to address the matter.
OTC Markets has indicated that the designation relates to a "public interest concern," prompting Quantum Genesis AI to request additional clarification. The company intends to continue cooperating with OTC Markets to address the situation. OTC Markets recently informed the company that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026, and Quantum Genesis AI plans to engage with OTC Markets at the earliest available opportunity to initiate that review process.
"We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation," said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. "Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process." The company remains committed to maintaining transparency with its shareholders and the broader investment community and intends to provide updates as additional information becomes available.
For investors and market observers, this development underscores the regulatory scrutiny facing companies in emerging technology sectors. The Caveat Emptor designation serves as a warning to investors about potential risks associated with the company's securities, which could impact trading activity and investor confidence. Quantum Genesis AI's proactive approach to addressing the designation reflects its stated commitment to responsible corporate governance, a factor that may influence stakeholder perceptions during the review process.
The outcome of this engagement with OTC Markets could have broader implications for how technology companies navigate regulatory frameworks in over-the-counter markets. As Quantum Genesis AI continues to focus on advancing next-generation technologies at the intersection of artificial intelligence and scientific innovation, resolving this regulatory matter may be crucial for maintaining its strategic trajectory. The company encourages stakeholders to monitor developments through its official channels, including its website at https://www.qgaicorp.com and its profile on OTC Markets at https://www.otcmarkets.com/stock/QGAI.
